Evidence map›Paper›PMID 37740824›Full record

ArticleNeuromolecular medicine2023

Modulation of Viability, Proliferation, and Stemness by Rosmarinic Acid in Medulloblastoma Cells: Involvement of HDACs and EGFR.

Alice Laschuk Herlinger, Gustavo Lovatto Michaelsen, Marialva Sinigaglia, Lívia Fratini, Gabriela Nogueira Debom, Elizandra Braganhol, Caroline Brunetto de Farias, Algemir Lunardi Brunetto, André Tesainer Brunetto, Mariane da Cunha Jaeger and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neuromolecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Alice Laschuk HerlingerCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil. aherlinger@hcpa.edu.br.
Gustavo Lovatto MichaelsenGraduate Program in Bioinformatics, Digital Metropolis Institute, Federal University of Rio Grande do Norte, Natal, RN, 59078-400, Brazil.
Marialva SinigagliaCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
Lívia FratiniCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
Gabriela Nogueira DebomPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, 90050-170, Brazil.
Elizandra BraganholPrograma de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, 90050-170, Brazil.
Caroline Brunetto de FariasCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
Algemir Lunardi BrunettoCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
André Tesainer BrunettoCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
Mariane da Cunha JaegerCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
Rafael RoeslerCancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil. rafaelroesler@hcpa.edu.br.
Universidade Federal do Rio Grande do Sul · BRCancer Research Institute of the Slovak Academy of Sciences · SKNational Institute of Science and Technology · IDUniversidade Federal de Ciências da Saúde de Porto Alegre · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 163018/2020-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 407765/2017-4Hospital de Clínicas de Porto Alegre 2021-0412
6 · The paper itself

Abstract

Medulloblastoma (MB) is a heterogeneous group of malignant pediatric brain tumors, divided into molecular groups with distinct biological features and prognoses. Currently available therapy often results in poor long-term quality of life for patients, which will be afflicted by neurological, neuropsychiatric, and emotional sequelae. Identifying novel therapeutic agents capable of targeting the tumors without jeopardizing patients' quality of life is imperative. Rosmarinic acid (RA) is a plant-derived compound whose action against a series of diseases including cancer has been investigated, with no side effects reported so far. Previous studies have not examined whether RA has effects in MB. Here, we show RA is cytotoxic against human Daoy (IC

Indexed as

Antineoplastic AgentsBrain NeoplasmsCerebellar NeoplasmsMedulloblastomaCell Line, TumorCell ProliferationChildEpidermal Growth FactorErbB ReceptorsHumansProto-Oncogene Proteins c-aktQuality of LifeAntineoplastic AgentsEGFR protein, humanEpidermal Growth FactorErbB ReceptorsProto-Oncogene Proteins c-aktBrain tumorEpidermal growth factor receptorHistone deacetylase inhibitorMedulloblastomaRosmarinic acidStem cell-like phenotype

Identifiers

PMID37740824
OpenAlexW4386981462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.